Secretome Therapeutics Puts Spotlight on Alternative Biotech Funding and Patient-Centric Development at ATW 2026

Secretome Therapeutics used its presence at Advanced Therapies Week 2026 in San Diego to underscore a dual focus on innovative financing strategies and deeply patient-centric clinical development. The private biotech highlighted its engagement with capital providers and advocacy groups as it advances programs in the cell and gene therapy arena.

Co‑founder and CEO Vinny Jindal joined a panel on alternative funding models for biotech, discussing approaches to financing innovation in capital‑intensive advanced therapies. This participation signals that Secretome is actively exploring nontraditional funding sources that could expand its capital base beyond conventional venture capital.

In parallel, VP of Clinical Development Salman Bhai took part in a fireside chat with Parent Project Muscular Dystrophy on how patient advocacy can shape early clinical development. Secretome emphasized that patient perspectives are increasingly central to trial design, endpoint selection, and overall clinical strategy rather than a secondary consideration.

By engaging closely with a rare disease advocacy organization at a high‑profile industry event, the company is building credibility within the neuromuscular and broader rare disease communities. This patient‑focused approach may support more relevant clinical endpoints, smoother trial recruitment, and stronger alignment with regulators and payers.

The combination of “rethinking capital” and embedding patient input into development suggests Secretome is working to de‑risk its pipeline both financially and clinically. While no specific financings or partnerships were announced, the week’s activities could enhance the company’s visibility and relationships, setting a constructive backdrop for future fundraising and collaboration efforts.